Merus regains some lost pride while Bicycle rides to even greater heights.
But winning EU approval for the novel anaemia pill was not straightforward, the Japanese firm says.
A low-key cancer discovery alliance sees Roche abandoning its earlier opposition to cell therapies.
The autoimmune target CD40 has yielded few hits despite years of research, but a few companies are keeping the faith.
AT132 has prompted more safety concerns, this time at a lower dose than before.
Axsome and Sanofi face FDA verdicts in depression and Pompe disease respectively, while a Keytruda combo ups the ante in kidney cancer.